See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
On May 18, 2020, Moderna announced encouraging preliminary results from the National Institute for Allergy and Infectious Diseases (“NIAID”)’s Phase 1 trial of the Company’s Covid-19 vaccione candidate, mRNA-1273. Following the announcement, Moderna’s stock price spiked nearly 20%.
However, the next day, the health news website STAT published an article casting doubt on the prudence of the Company’s optimism and highlighting the lack of key data in Moderna’s statements. Specifically, the article stated that vaccine experts had concluded that “there’s really no way to know how impressive — or not — the vaccine may be.”
Following the article, Moderna’s stock price plummeted, closing at $57.71 per share on May 27, 2020, even lower than Moderna was trading prior to the announcement of positive preliminary results. Further, related news articles have leveled accusations of insider trading against Moderna executives.